|
Business
Colorado BioScience Association Announces Nine New Board Members
© Business Wire 2008
2008-05-02 22:55:05 - www.cobioscience.com - Nine new board members have been elected to the Colorado BioScience Association (CBSA) 40-member Board of Directors. The announcement is made by Chris Shapard, CBSA Deputy Director, who says the election occurred at the Association's recent 2008 All-Member Meeting.
Newly elected CBSA board members include: Jim Chrisman, Senior Vice President, Forest City --
|
|
| href="http://www.fitzscience.com" title="http://www.fitzscience.com" target="_blank">www.fitzscience.com; John Dunning, President and CEO, Clarimedix; Leslie Leinwand, Director, Colorado Initiative in Molecular Biotechnology and Professor, MCD Biology Department, University of Colorado -- www.colorado.edu; Terry Opgenorth, Chief Operating Officer, MicroRx and NeoTREX, Colorado State University Research Foundation -- www.csurf.org; John Poate, Vice President for Research and Technology Transfer, Colorado School of Mines - www.mines.edu; Rae Reynolds, President, Kaleidoscope Group; Jim Skrine, Executive Director of Quality, Amgen -- www.amgen.com; Rulon Stacey, President and CEO, Poudre Valley Health System -- www.pvhs.org; and Dan Stinchcomb, Chief Executive Officer and Co-Founder, Inviragen -- www.inviragen.com.
Bios follow of the new CBSA board members:
-- Jim Chrisman is the Senior Vice President for Forest City, the development company working in partnership with the Fitzsimons Redevelopment Authority to create a nationally and internationally renown life science park. Chrisman is the principal in charge of the Fitzsimons project on behalf of Forest City. In addition, he is responsible for office, retail, industrial and multi-family development at the former Stapleton International Airport which Forest City is transforming into a new community of 12,000 homes, 35,000 jobs and more than 1,100 acres of parks and open space. Prior to joining Forest City Stapleton, Inc., Chrisman worked as a Vice President for the Stapleton Development Corporation, where he managed the conveyance of the property from the City and County of Denver to the private sector and the Stapleton Redevelopment Foundation, where he managed the preparation of the award winning Stapleton Development Plan. Prior to that, he worked for Disney Development Company, Watt Industries, and Cadillac Fairview Corporation in southern California. He is currently on the Board of Directors of the local chapter of the National Association of Office and Industrial Properties. He holds a Bachelor of Science in Applied Mathematics and Administration and Management Science from Carnegie-Mellon University and a M.B.A. from the University of California, Berkeley.
-- John Dunning is President and CEO of CLARIMEDIX INC, a therapeutic medical device company based in Boulder, CO. Dunning brings a diverse background with significant start-up experience and an understanding of the financing and management processes associated with equity-backed companies. Prior to his time with CLARIMEDIX, he was an investor at Wasatch Venture Fund, where he focused on a mixture of life science and technology investing while successfully raising a $12 million side car fund for Wasatch. Prior to joining Wasatch, Dunning contributed at several start-ups in the San Francisco Bay Area where he had roles in operations and business development. He holds a B.A from the University of Oregon and an M.B.A. from Thunderbird, the American Graduate School of International Management.
-- Dr. Leslie Leinwand is a Molecular, Cellular, and Developmental Biology (MCDB) Professor and Director of the Colorado Initiative in Molecular Biotechnology. She has been at the University of Colorado since 1995. She was recruited here to be Chair of MCDB. She received her Bachelor's degree from Cornell University, her PhD from Yale University and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado. While at Albert Einstein she became a Full Professor and was Director of the Cardiovascular Research Center. Once moved to Colorado, along with Michael Bristow, she founded the intercampus University of Colorado Cardiovascular Institute which promotes research and training in cardiovascular disease. They, along with Eric Olson at the University of Texas, Southwestern Medical Center, founded Myogen, Inc. which was recently sold to Gilead Pharmaceuticals. Her work as a cardiac biologist is of importance to both basic scientists and clinicians. The interests of Dr. Leinwand's laboratory are the genetics and molecular physiology of inherited diseases of the heart. The study of these diseases has required multidisciplinary approaches, involving molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of human tissues. To accomplish this, Dr. Leinwand has developed a highly collaborative group in Boulder, bringing together specialized basic scientists and clinical cardiologists. Her laboratory's efforts are well-funded by multiple grants from the National Institutes of Health and her teaching is recognized by funding from the Howard Hughes Medical Institute's Professor Program. She is also the Principle Investigator of the HHMI program called the Biological Sciences Initiative which supports undergraduate research, K-12 outreach and educational programs for high school teachers.
-- Terry Opgenorth serves as COO for MicroRx and NeoTREX, the enterprise arms of Colorado State University's Infectious Disease and Cancer Superclusters. He joined CSU Ventures, Inc. in 2007 after 20 years with Abbott Laboratories, North Chicago, IL. His last position at Abbott was as Divisional Vice President of Metabolic Disease Research, Antiviral Research and Target-Lead Discovery Research for Abbott's Global Pharmaceutical Research and Development division. He championed a number of biotech collaborations, and teams he led advanced 10 novel drug candidates to clinical development status with atrasentan reaching Phase III and NDA filing; others are in various stages of development. He was also a Research Fellow in Abbott's Volwiler Society. He serves on Scientific Advisory Boards for Keystone Symposia and Euroscreen, SA, and is a Section Editor for Current Opinions in Investigational Drugs. He is an author on 130 peer-reviewed publications, 9 book chapters or reviews, and an inventor on 3 patent applications. Dr. Opgenorth holds a BA in Biology from Calvin College, and MS and PhD degrees in Physiology from University of Illinois-Urbana.
-- John Poate is Vice President of Research and Technology Transfer, Colorado School of Mines; a position he assumed in January 2006. Prior to assuming his present position, he was Chief Technology Officer and Vice President of Axcelis Technologies; a position he assumed in June, 2000. He was also Dean, from 1997 - 2000, of the College of Science and Liberal Arts of the New Jersey Institute of Technology (NJIT). The bulk of Poate's research career was spent at Bell Labs as Department Head of the Silicon Processing Research Department. Poate obtained his BSc and MSc in Physics from Melbourne University and PhD in Nuclear Physics from The Australian National University. He has over 300 publications in archival journals and 12 patents. He is past President and Councillor of the Materials Research Society and past Chair of the Division of Materials Physics of the American Physical Society. Poate is a Fellow of the American Physical Society and Editor of Applied Physics Reviews. He is Past Chair of the Physical and Engineering Sciences Panel for NATO. In 2002 he received the John Bardeen Award of The Metallurgical Society. In March 2008 he was inducted as a foundation Fellow of the MRS.
-- Rae Reynolds, President of Kaleidoscope Group, has 30 years of experience in marketing and business development in the biotech industry. Reynolds served as the Vice President of Marketing for Cochlear Corporation to launch, and promote a market leading product line, build the market, and complete a successful IPO. She has helped commercialize and promote a range of additional biotech products and services through skills in competitive analysis and positioning, product launch, and corporate partnering and acquisition. Her experience includes assisting entrepreneurial companies secure early-stage capital through the NIH's Small Business Innovation Research (SBIR) grant process. Reynolds earned a BA in Economics from the University of Denver. She attended Johns Hopkins School of Advanced International Studies, and received a Masters in Planning from University of Colorado.
-- Jim Skrine, Executive Director of Quality, oversees the Quality Assurance, Product Quality, Quality Control, Validation and Compliance Groups for Amgen Colorado. Immediately prior to his current post, Skrine served as Director of Manufacturing and Plant Manager for Amgen Commercial Bulk Manufacturing in Thousand Oaks, California. There he had oversight for the manufacturing of the drug substance for six commercially marketed products; Epogen(R), Aranesp(R), Neupogen(R), Neulasta(R), Infergen(R), and Stemgen(R). He has been at Amgen for nearly seventeen years and began his career as a Protein Chemist in the Research and Development organization. Skrine earned a Bachelor's degree in Mathematics from Saint Vincent College in Latrobe, Pennsylvania and a Bachelor's degree in Biology from the University of California, Santa Barbara. He is currently a member of the Parental Drug Association (PDA) and serves on the Board of Directors for HospiceCare of Boulder and Broomfield Counties.
-- Rulon Stacey, Ph.D., first came to Colorado in 1989 when he was appointed as the Chief Executive Officer of St. Vincent General Hospital in Leadville. He served in that post for 5 years. During that time he was recognized by the leading healthcare administration journal as one of the 12 "up and coming" healthcare administrators in the country for his innovative plans to address the issues specific to rural healthcare. After a brief stay in Chicago, Dr. Stacey was appointed as the President and Chief Executive Officer of the Poudre Valley Health System in Fort Collins in 1996. During his stay in Fort Collins Dr. Stacey has become nationally recognized for his innovative approach to working with physicians to better provide healthcare in a seamless environment. In 2004 the Poudre Valley Health System became the first organization in any industry to receive the prestigious Peak Award from the Colorado Performance Excellence Institute for their work on the quality process. In 2005 and 2006 Poudre Valley Health System was a finalist for the prestigious Malcolm Baldrige National Quality Award. Dr. Stacey currently serves at the Regent for Colorado for the American College of Healthcare Executives, and has been asked to serve as the only healthcare administration appointment to the American Hospital Association's Committee on Governance. Dr. Stacey has a bachelor's degree in Economics and a master's degree in Health Administration from Brigham Young University. He has a Ph.D. from the Graduate School of Public Affairs of the University of Colorado at Denver, where he also was named a Milstein Scholar for writing the best dissertation of the year in 2000.
-- Dan Stinchcomb is Chief Executive Officer and co-founder of Inviragen, a biotechnology company focused on developing life-saving vaccines for emerging infectious diseases worldwide. Since initiating operations for Inviragen in January, 2005, Dr. Stinchcomb successfully raised over $5.2 million in grant and seed investor funding, established Inviragen's product and business strategies, opened its office and laboratory facilities in Fort Collins and established key collaborations with international vaccine manufacturers, non-profit vaccine initiatives, government research organizations and university researchers. Inviragen won the CBSA Venture Showcase competition in 2005 and the Rising Star Award in 2007. Dr. Stinchcomb brings over twenty years of biotechnology management and scientific experience to Inviragen. Formerly, Dr. Stinchcomb was Executive Vice President of Research and Development at Heska Corporation and held scientific management positions at Ribozyme Pharmaceuticals (now Sirna, acquired by Merck) and Synergen (acquired by Amgen). Prior to joining Synergen, Dan was an Associate Professor in Cellular and Developmental Biology at Harvard University. Dr. Stinchcomb is an inventor on over 20 issued US patents and has authored more than 30 scientific articles. He received his PhD degree in Biochemistry from Stanford University and a BA degree from Harvard. Dr. Stinchcomb is also an Adjunct Professor of Molecular Biology and Biochemistry at Colorado State University.
In related action, seven existing board members were elected to reappointments on the CBSA board. These include: Sean Moriarty, QLT-USA; Jack Wheeler, MicroPhage; Rick Jory, Sandhill Scientific; John Eckstein, Fairfield & Woods; Maggie Holben, Absolutely Public Relations; Tom Roach, Ernst & Young; and Lynn Taussig, University of Denver.
About Colorado BioScience Association
CBSA is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 400 members, CBSA actively works to promote the growth of the industry by working for a better business environment, grow the state's biotech workforce, fight for policies that support a strong bioscience industry in the state and speak with a single voice on behalf of the industry. For more information, visit www.cobioscience.com.
Colorado BioScience Association
Christine Shapard, 303-592-4089
cshapard@cobioscience.com
Deputy Director
or
Absolutely PR on behalf of Colorado BioScience
Association
Maggie Chamberlin Holben, 303-984-9801
maggie@absolutelypr.com
|
| Disclaimer:
(c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
|
 |
|
